HOWL Werewolf Therapeutics, Inc.

NASDAQ
$0.40

Werewolf Therapeutics, Inc. (HOWL) is expected to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -19.1% since its last earnings release on July 31, 2026.

Werewolf Therapeutics Beat Consensus Estimates
Friday, July 31, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 29
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.22)
Rev est $999
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.37

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology